The Renal Denervation Market Size was valued at USD 1.11 Billion in 2023 and is projected to grow from USD 1.53 Billion in 2024 to USD 15.09 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 33.03% during the forecast period (2024 - 2032).The increasing spread of hypertension and the rise in clinical studies are market drivers expediting the market’s expansion.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The rise in the spread of chronic diseases and the growing spread of hypertension is driving Market CAGR for renal denervation. One of the key drivers of market growth is the increase in occurrences of therapy-resistant hypertension. One of the most prevalent diseases in the world is hypertension. More than 360,000 Americans died in 2013 as a result of high blood pressure, according to the Centers for Disease Control and Prevention (CDC). From 17,307 per 100,000 people in 1990 to 20,525 per 100,000 people in 2015, hypertension has increased. However, renal denervation therapy has successfully decreased blood pressure. The benefits of these therapies, such as their persistent effects, shorter treatment times, and improved safety levels, are thereby promoting market expansion. The development of renal denervation devices is also anticipated to fuel market growth.
As an illustration, the development of catheter-based interventional therapy to ablate the renal nerve has demonstrated excellent benefits in the management of blood pressure in patients presenting with complaints of resistant hypertension. Additionally, the catheter-based approach facilitates the denervation of particular nerves and seems to be safer for patients.
The amount of alcohol sold in 15 US states increased by 4% from January to August 2020 compared to a year earlier, as per the National Institute on Alcohol Abuse and Alcoholism. This could increase the risk of hypertension and encourage the use of renal denervation devices. Consequently, it is projected that the studied market would expand over the coming years as a result of factors such as an increase in product sales, the introduction of new products, and an increase in health problems connected to hypertension.
Growth in the market is also predicted to be fueled by an increase in clinical studies, research, and development related to renal denervation devices, as well as the long-term advantages of renal denervation treatments. For instance, according to research that appeared in April 2022 issue of the journal Nature, more than 80% of Thai patients with resistant hypertension benefited from the effectiveness of renal nerve denervation, which was maintained over a longer follow-up period without any intervention-related side effects.
It is also projected that the development of the healthcare infrastructure in emerging economies and the availability of substitutes and better technology, such as micro-infusion for renal denervation systems, will accelerate market expansion. For instance, the renal denervation system is based on micro-infusion from Mercator MedSystem. It distributes substances at a specified location to denervate the renal artery, lowering the patient’s blood pressure. Thus, driving the Renal Denervation Market revenue.
The Market segments of Renal Denervation, based on product includes Simplicity, Vessix (V2), EnligHTN, Paradise, Iberis, and Others. The biggest market share for renal denervation was simplicity. Due to its delivery of low-level radiofrequency energy and consequent reduction in the risk of radiation exposure to body tissues from high-level radiofrequency, this system is most frequently employed to treat hypertension. Additionally, it provides a minimally intrusive method for treating severe hypertension.
The Renal Denervation Market segmentation, based on technology, includes Radiofrequency, Ultrasound, Micro-infusion, and Others. Due to its benefits, including safety and time efficiency, the radiofrequency category had the biggest market share. As ultrasound devices get around the restrictions of radiofrequency-based systems, the segment is expected to grow at the highest CAGR. The nerves are destroyed by ultrasound energy using high-frequency sound waves without making direct contact with the tissues, which lessens damage to the renal arteries.
The Market segmentation of Renal Denervation, based on end-user, includes hospitals, Clinics, Ambulatory surgery centers, and Others. Due to the rising demand for renal denervation, the hospitals segment dominates the end-user section of the worldwide renal denervation market.
Figure 1: Renal Denervation Market, by End-User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. Due to the increasing number of requests for FDA approvals in the U.S., North America is expected to dominate the market. As an illustration, the FDA has permitted Medtronic to begin a key Investigational Device Exemption (IDE) trial to test the Symplicity Spyral renal denervation system in patients with hypertension.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: RENAL DENERVATION MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe’s Renal Denervation Market accounts for the second-largest position in the market. This is a result of increased R&D efforts for the creation of effective devices. The prevalence of drug-resistant hypertension will also rise, fueling the area's expansion. Further, the UK market of Renal Denervation held the largest market share, and the Germany market of Renal Denervation was the quickest-growing market in the North American region
The Asia-Pacific Renal Denervation Market is anticipated to expand at the quickest CAGR. This is due to the abundance of unmet medical needs for the treatment of hypertension, growing knowledge of the utilization of cutting-edge technology such as renal denervation systems, and the high prevalence of resistant hypertension. Moreover, China market of Renal Denervation held the fastest CAGR, and the India market of Renal Denervation was the quickest-growing market in the Asia-Pacific region.
Renal Denervation Key Market Players & Competitive Insights
Leading market players are investing largely in research & development-related activities to extend their product/service lines, which will aid the market of Renal Denervation, to grow faster. Market leaders are also adopting a range of strategies to expand their worldwide position, with important market developments including new product launches & developments, contractual agreements among companies with complementary service lines, mergers & acquisitions, increased investments, & collaboration with other organizations having complementary products and services. To grow in a competitive and rising market climate, the Renal Denervation industry needs to offer cost-efficient products.
Producing locally to cut operational expenses is one of the prime business strategies used by manufacturers in the Renal Denervation industry to benefit clients and increase the market sector. In recent years, the Renal Denervation industry has served with some of the key perks of medicine. Major players in the Renal Denervation Market, including Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiotonic, Cordis, Kona Medical, Sound Intervention, Terumo, and others are attempting to increase market growth via investing in research and development operations.
ReCor Medical is a manufacturer of medical equipment and a leader in the development of Ultrasound Renal Denervation (ADN) technology for the management of hypertension, one of the most common medical disorders. ReCor Medical creates and produces the Paradise Ultrasound Renal Denervation system, which uses ultrasound energy to treat overactive renal nerves during a single minimally invasive operation to control high blood pressure. Only exploratory use of the Paradise System is permitted within the United States. only for distribution in nations with CE certification. ReCor Medical Inc. is the owner of the trademark The Paradise System. In February 2023, According to a study, the Paradise ultrasonic renal denervation (uRDN) device from ReCor Medical successfully lowered blood pressure. The Radiance clinical trial findings are significant because they confirm the Paradise uRDN System's usefulness as a supplementary therapy for the treatment of hypertension.
Designing, developing, producing, and marketing medical devices and solutions are the core competencies of Medtronic Plc (Medtronic), formerly known as Medtronic Inc. It provides goods for the treatment of conditions such as diseases of the heart valves, heart failure, peripheral vascular, venous renal, and neurological diseases, spine and musculoskeletal disorders, and ear, nose, and throat conditions. It also provides goods for the treatment of aortic, coronary, peripheral, and peripheral vascular diseases. For the dentistry and orthopedic businesses, it also offers biologic solutions. In the regions of Asia Pacific, Europe, the Americas, the Middle East, and Africa, it offers its products to hospitals, third-party healthcare providers, clinics, institutions, and government healthcare programs. Dublin, Ireland serves as the company's headquarters. In September 2022, According to trial results released by Medtronic, the Symplicity renal denervation device significantly lowers blood pressure. The radiofrequency renal denervation (RF RDN) procedure was performed on individuals in the SYMPLICITY HTN-3 clinical trial using first-generation Symplicity. Results showed that when compared to a sham control group, office, and ambulatory blood pressure decreased statistically significantly.
Key Companies in the Renal Denervation Market include
ReCor Medical
St. Jude Medical
Cardiosonic
Cordis
Kona Medical
Sound Intervention
Terumo
Renal Denervation Industry Developments
July 2023:The new European Hypertension Society (ESH) recommendations, which emphasize the importance of renal denervation (RDN) as a component of the hypertension therapy pathway, are very exciting to Medtronic. The recommendations were released concurrently in the Journal of Hypertension and during the ESH 32nd Annual Meeting.
Simplicity
Vessix (V2)
EnligHTN
Paradise
Iberis
Others
Radiofrequency
Ultrasound
Micro-infusion
Others
Hospital
Clinics
Ambulatory surgery centers
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.11 Billion |
| Market Size 2024 | USD 1.53 Billion |
| Market Size 2032 | USD 15.09 Billion |
| Compound Annual Growth Rate (CAGR) | 33.03% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technology, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiotonic, Cordis, Kona Medical, Sound Intervention, and Terumo |
| Key Market Opportunities | Rising research & development activities across healthcare |
| Key Market Dynamics | Increasing cases of hypertension among individuals |
Renal Denervation Market Highlights:
Frequently Asked Questions (FAQ) :
The Renal Denervation Market size was valued at USD 1.11 Billion in 2023.
The market is projected to grow at a CAGR of 33.03% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiotonic, Cordis, Kona Medical, Sound Intervention, and Terumo.
The radiofrequency category dominated the market in 2023.
Simplicity had the largest share of the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
